Cure My Disease

Don't miss your cure!

 Log in / Sign up

Muscle disease may confuse heart attack tests: study aims to clarify

NCT ID NCT03660969

NEW Diagnosis Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

People with muscle disease often have high levels of a heart protein called troponin, even when their heart is fine. This can make it hard for doctors to tell if chest pain is a heart attack. Researchers are comparing two types of troponin tests in patients with and without muscle disease to see how the tests behave. The goal is to help doctors interpret these tests more accurately and avoid unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to clearer guidelines for interpreting troponin tests in people with muscle disease, helping doctors avoid unnecessary heart procedures and focus on the right diagnosis.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may not apply to all muscle conditions or hospital settings, and the findings might not change practice if the differences between tests are small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

797 people

The number who actually took part.

Started

Jan 2018

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive participants which have been or currently are in treatment for a muscle disease at the University hospital of Basel, at the Canton Hospital of Aarau, University Hospital of Zürich or Bern or at the Medical University of Innsbruck, or who received a new diagnosis/suspicion of such a disease will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnostic or suspicion of muscle disease as presence of specified keyword in patient's file or as screened by colleagues of the rheumatology, neuromuscular or other medical clinics. * Patient consent available Exclusion Criteria: * Patient's refusal * Age \<18 years old * Terminal kidney insufficiency with need for dialysis. * Temporary exclusion criteria : Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\>100 bpm, \<90 systolic BP, evidence of organ dysfunction).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle atrophy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

injury Muscle Cramp Muscle Spasticity muscle tissue disorder Muscle Weakness muscular atrophy Myalgia myopathy skeletal muscle disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle atrophy Muscle cramp Muscle damage Muscle injury Muscle soreness Muscle spasticity Muscle weakness Myopathy

Contacts and locations

Locations

  • Canton Hospital of Aarau

    Aarau, Canton of Aargau, 5001, Switzerland

  • Inselspital Bern

    Bern, 3010, Switzerland

  • Medical University Innsbruck

    Innsbruck, Innsbruck, 6020, Austria

  • University Hospital Basel

    Basel, Basel, 4056, Switzerland

  • University Hospital Zürich

    Zurich, Canton of Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.